A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Conditions: Multiple Myeloma; Minimal Residual Disease Sponsors: FengYan Jin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: Iberdomide; Drug: Daratumumab/rHuPH20 Co-formulation Sponsors: Barbara Ann Karmanos Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals; Multiple Myeloma Research Consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: AZD0305 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
18F-Fluciclovine PET/CT in Multiple Myeloma
Conditions: Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Relapsed and/or Refractory Multiple Myeloma (RRMM) Interventions: Drug: 18F-fluciclovine injection; Procedure: 18F-FDG PET/CT Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: Belumosudil mesylate Sponsors: M.D. Anderson Cancer Center; Sanofi US Services, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Dynamic Frailty Assessment for Guiding the Treatment in Older Adults With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma; Frailty Sponsors: FengYan Jin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
Conditions: Multiple Myeloma Interventions: Drug: Teclistamab; Drug: Talquetamab; Drug: Daratumumab SC Sponsors: University of Miami; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Multiple Myeloma Prognostic Indices
Conditions: Multiple Myeloma; Hematologic Diseases Interventions: Other: blood viscosity , albumin / fibrinogen ratio and red cell distribution Sponsors: Assiut University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Conditions: Multiple Myeloma Interventions: Drug: Lenalidomide Sponsors: Starton Therapeutics, Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Conditions: Multiple Myeloma; Monoclonal Gammopathy of Renal Significance Interventions: Drug: Cyclophosphamide; Drug: Bortezomib; Drug: Dexamethasone; Drug: Daratumumab Sponsors: Memorial Sloan Kettering Cancer Center; Janssen Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Conditions: Relapse/Refractory Multiple Myeloma Interventions: Biological: DeepTag-GPRC5D Targeted CAR T-cells Sponsors: He Huang; Yake Biotechnology Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: IBI3003 Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
Conditions: Relapsed or Refractory Non-Hodgkin ' s Lymphoma; Relapsed or Refractory Multiple Myeloma Interventions: Drug: BEBT-908 for injection Sponsors: BeBetter Med Inc Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
Conditions: Multiple Myeloma; M Protein Sponsors: Zhujiang Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Behavioral: THRIVE-M Sponsors: Massachusetts General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
